Icon times
Torrent Pharmaceuticals Stock Fundamental Analysis - Financial Results & Equity Research | Invest Yadnya Stock-o-Meter

Torrent Pharmaceuticals

CompanyOver

 / 
error iconThis ratio is already added in the table

About

Incorporated in 1959, Torrent Pharma (TPL) is the eighth largest player in the domestic market with and is among the top five players in therapeutic segments of Cardiovascular, CNS, Gastro-Intestinal, Diabetology, Anti-Infective, VMN and Pain Management solutions.. Torrent Pharma produces both branded generics & non branded generics. Company with 9 Manufacturing units & 1 R&D centre spread across boundaries catering to key markets of India, Brazil, USA and Germany. Company derives 42% of revenue from Domestic formulations,21% of Revenue from US Formulations,13% of revenue from Europe,9% of revenue from Brazil

Highlights

Performing rate for the company

Price Chart (Only Standalone)

Track the companies of Group.

Relaince Group

Sector: Refineries

Market Price

2,529.50

Market Cap(₹Cr.)

2,529.50

-90.00

Quarterly Results ( Figures in Rs. Crores.)

No Data is available.

Profit & Loss ( Figures in Rs. Crores.)

No Data is available.

Balance Sheet ( Figures in Rs. Crores.)

No Data is available.

Cash Flows ( Figures in Rs. Crores.)

No Data is available.

Historical Growths

Compounded Sales Growth
Compounded Profit Growth
Compounded Expense Growth
Stock Price CAGR
Sales Growth Profit Growth Expense Growth Stock Price CAGR

Ratios ()

No Data is available.

Major Shareholders

No Data is available.

Shareholders more than 1%

No Data is available.

Fund houses invested in the stock (Figures in % Equity Capital )

No Data is available.

Corporate Action

No Data is available.
No Data is available.
No Data is available.
No Data is available.

Documents

Presentation & Earning Calls

Annual Reports

Credit Rating

No document is available
No document is available
No document is available
No document is available.

Overview

Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.

Business area of the company

Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.

Manufacturing facilities

The company’s manufacturing facilities are loaced at Indrad, Dahej, Baddi, Sikkim Unit I & II, Sikkim Unit III, Vizag, Pithampur, Levittown Pennsylvania and HSE Forum.

Awards and recognition

  • 1984-85 Received Chemexcil Export Award
  • 1984-85 Received Udyog Ratna Award
  • 1985-86 Received Chemexcil Export Award
  • 1986-87 Received Chemexcil Export Award
  • 1986-87 Received IDMA Quality Excellence Award
  • 1986-87 Received Export Award from Govt. of Gujarat
  • 1987-88 Received Export Award from Govt. of Gujarat
  • 1989-90 Received Chemexcil Trishul Award for highest Pharma Exports
  • 1989-90 Received IDMA Quality Excellence Award
  • 1988-89 Received Chemexcil Export Award
  • 1990-91 Received Export Award from Govt. of Gujarat
  • 1990-91 Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship
  • 1991-92 Received Export Award from Govt. of Gujarat
  • 1991-92 Received National Export Award
  • 1992-93 Received IDMA Quality Excellence Award
  • 1999-00 GCCI Export Appreciation Award
  • 1999-00 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility.
  • 2000-01 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2001-02 Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation.
  • 2001-02 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy forits API manufacturing facility
  • 2002-03 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2009-10 Baddi Plant awarded Five Star rating by British Safety Council
  • 2012-13 Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2014-15 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2017-18 Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017-18 Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category

Accreditation

Approvals research centre

  • National GLP Compliance Monitoring Authority, India*
  • National Accreditation Board for Testing & Calibration Laboratories (NABL), India*
  • ISO 14001:2004 and OHSAS 18001:2007, ISOQAR Ltd., UK*
  • ISO 50001 : 2011, ISOQAR Ltd. UK*

(*Also applicable for Bio-Evaluation Center)

Bio-evaluation centre accreditations

  • The Drug Controller General (India) (DCGI)
  • ANVISA (BRAZIL)
  • Ministry of Health (UAE)

Studies inspected and approved

  • USFDA
  • AFFSAPS (ANSM)
  • DKMA
  • AGES
  • ANVISA

Studies accepted by Regulatory Agencies in:

  • Russia
  • CIS Countries
  • Australia
  • ASEAN countries
  • South Africa
  • African countries
  • South American countries

Milestones

  • 1959: U. N. Mehta started Pharma operations.
  • 1971: Trinity Laboratories renamed as Torrent Pharmaceuticals Limited.
  • 1980: First manufacturing facility set up at Vatva in Ahmedabad
  • 1983: Entry into the international markets. First Export order to USSR received
  • 1984: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1984: Torrent Laboratories Limited received Udyog Ratna Award.
  • 1985: Torrent Laboratories Limited received IMC Golden Jubilee Endowment Award for Export Performance.
  • 1985: Torrent Exports Limited received Export Award From Govt. of Gujarat.
  • 1985: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1985: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1986: Torrent Laboratories Limited received IDMA Quality Excellence Award.
  • 1986: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1987: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1987: Torrent Exports Limited received Export Award from Govt. of Gujarat.
  • 1989: Second manufacturing plant commissioned at Indrad
  • 1989: Torrent Exports Limited received Chemexcil Trishul Award for highest Pharma Exports.
  • 1989: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1988: Torrent Laboratories Limited received Chemexcil Export Award.
  • 1990: Torrent Exports Limited received National Export Award.
  • 1990: Pride of Asia International award for excellence in Pharmaceuticals Products by international Friendship.
  • 1992: Torrent Pharmaceuticals Limited received IDMA Quality Excellence Award.
  • 1995: Torrent Gujarat Biotech Limited plant commissioned.
  • 1996: U N Mehta bestowed with the title of Corporate Business Man of the Year
  • 1998: Torrent Exports renamed as Torrent Ltd. as part of restructuring and consolidation exercise.
  • 1998: State-of-the-art R&D Centre commissioned.
  • 1998: Torrent Pharmaceuticals Limited acquires Pharma related investments and business of Torrent Exports Limited.
  • 1999: Restructuring of Torrent Pharmaceuticals Ltd. through formation of three new divisions – Prima, Vista, Psycan.
  • 1999: First New Chemical Entity Patented by Torrent Research Center
  • 1999: GCCI Export Appreciation Award
  • 1999: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility
  • 2000: Torrent Research Centre received OECD Standards of Good Lab. Practices Certificate from Dutch Health Ministry.
  • 2000: Indrad Plant received ISO 9001:2000 Certificate
  • 2001: Torrent Pharma ranked in the top 10 Indian Companies in terms of Return on Capital Employed (ET - BCG Study Feb - 2001).
  • 2001: Torrent Pharmaceuticals bagged the 'Best Suppliers' award by the Sri Lankan State Pharmaceutical Corporation
  • 2001: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility and Silver Trophy for its API manufacturing facility
  • 2001: Torrent do Brasil Ltda. set up in Brazil
  • 2002: Discovered and patented AGE (Advanced Glycosylation End-products) molecule.
  • 2002: Torrent Pharma's Indrad Plant receives ISO 14001:1996 and OHSAS 18001:1999
  • 2002: Torrent's R&D Centre received ISO/IEC 17025:1999 for its facilities by National Accreditation 2002:
  • 2002: Board for Testing and Calibration Laboratories (NABL).
  • 2002: Addition of a new marketing division, MIND
  • 2002: Dual Retard Inlay Technology, Compact Tablet Technology, Gastro Retentive System and Multiparticulate / Matrix Based SR / Modified Release Formulations developed indigenously by Torrent Research Center (2002)
  • 2002: Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award 2003 for both Formulations and API manufacturing facilities
  • 2002: Brazilian Sanitary Surveillance Agency accredited Torrent's R&D Centre with ANVISA, authorizing it to conduct Bioequivalance Studies.
  • 2003: Torrent Pharma Inc. set up in USA.
  • 2003: GMP Certification received from European Union by Torrent Pharmaceuticals Manufacturing Plant
  • 2003: Torrent Pharma Philippines Inc. set up.
  • 2004: Torrent Pharma's manufacturing facility at Indrad received MHRA (UK) and TGA (Australia) approvals
  • 2004: Restructuring of marketing divisions and addition of new division, Delta.
  • 2004: Torrent Australasia Pty Ltd. incorporated in Australia
  • 2005: New manufacturing unit at Baddi, Himachal Pradesh, set up to cater to domestic formulations market.
  • 2005: Torrent Pharma signed an agreement with Novo Nordisk India to establish a new, dedicated formulation and packaging facility for Insulin, exclusively for Novo Nordisk.
  • 2005: Acquired Heumann Pharma GmbH & Co Generica KG, a Pfizer group company, in Germany.
  • 2005: Two new marketing divisions- AXON and NEURON set up to cater to neuropsychiatry segment.
  • 2005: Entered into a research collaboration with AstraZeneca for developing novel anti-hypertensive drug.
  • 2005: Torrent Pharma's QC department at Chhatral manufacturing plant accredited with ISO/IEC- 17025 by NABL
  • 2006: The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got US FDA approval
  • 2006: Torrent Pharma and Pharma Dynamics (Pty) Ltd, South Africa signed a Technical Agreement for supplies of a range of products
  • 2007: Indrad Plant certified with ISO 9001: 2000 (Quality Management System), ISO 14001:2004 (Environmental Management System) and OHSAS 180001:1999 (Occupational Health and Safety Management System) by ISOQAR, UKAS accredited body
  • 2007: Construction of Sikkim Plant started
  • 2008: Baddi Plant received GMP certification from Government of Upper Bavaria, Germany
  • 2009: Commissioned dedicated formulation and packaging unit for manufacturing Insulin exclusively for Novo Nordisk
  • 2009: Entered into license and supply agreement with AstraZeneca for marketing its products in international market
  • 2009: Baddi Plant awarded Five Star rating by British Safety Council
  • 2010: Baddi Plant received OHAS Audit 18001:2007certification; facility approved by the regulatory authority of Uganda
  • 2010: An advanced facility for Stability Studies set up at Indrad Plant
  • 2010: Entered into the therapeutic area of Gynaecology
  • 2010: Commenced commercial operations of Laboratories Torrent S.A. de C.V., Mexico
  • 2010: Started construction of Dahej manufacturing facility
  • 2010: Commissioned a subsidiary in United Kingdom and Romania
  • 2010: Torrent Research Center develops Long Acting Injectables technology
  • 2010: Foray into oncology segment
  • 2011: Sikkim Plant commences operation
  • 2011: Indigenous Nasal Drug Delivery system developed by Torrent Research Center
  • 2011: Set up Sparsh, a dedicated division to cater to Dermatology Segment
  • 2012: Indrad Plant awarded Sword of Honor for Occupational Health & Safety by British Safety Council
  • 2012: Topical Foams system developed by Torrent Research Center
  • 2013: Torrent Pharma enters into a licensing agreement with Reliance Life Sciences for three biosimilars - Rituximab, Adalimumab, and Cetuximab
  • 2014: Acquired Elder Pharma's identified Indian Branded Formulation Business in India and Nepal
  • 2014: Launched Nephro, a dedicated division to cater to the Nephrology Segment
  • 2014: Torrent Pharma's Dahej Plant commences operations
  • 2015: Torrent acquires 100% stake of Zyg Pharma
  • 2015: Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014
  • 2016: Dahej Plant receives USFDA approval
  • 2016: Acquired API manufacturing Unit of Hyderabad based Glochem Industries Limited
  • 2017: Acquired Unichem’s Domestic and Nepal business and also its Sikkim manufacturing facility.
  • 2017: Listed amongst top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine
  • 2017: Executive Chairman, listed by Business World Magazine, amongst India's Most Valuable CEOs in Large Category
  • 2017: Acquired Women Healthcare brands from Novartis
  • 2018: Acquired US based Bio-Pharm, Inc. (BPI) which includes US FDA registered manufacturing facility. This is Torrent's first overseas manufacturing unit.
  • 2019: Torrent & Glenmark sign licensing agreement for co-marketing of Remogliflozin Etabonate in India
Brands Of Torrent Pharmaceuticals

Brands Of Torrent Pharmaceuticals

undefined

Comment

Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya